Policy & Regulation
Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy
24 June 2026 - Biotechnology company Thalia Therapeutics plc (AIM: THAT) disclosed on Wednesday that it has agreed to acquire clinical-stage oncology company Sanmirna Therapeutics Inc, adding its lead...
Circio and Tcelltech partner on next-generation CAR-T cell therapy research
24 June 2026 - Circio Holding ASA (OSE:CRNA) a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, announced on Wednesday that it has formed a CAR-T ce...
Essange Reagents and Gentian Diagnostics agree collaboration on diagnostic assay development
24 June 2026 - Gentian Diagnostics (OSE:GENT), a Norway-based developer of in vitro diagnostic reagents, said on Wednesday that it is planning to enter into a collaboration agreement with Essange Reag...
Haisco agrees licensing deal with Nuvectis for two drug candidates
24 June 2026 - Chinese pharmaceutical company Haisco Pharmaceutical Group Co Ltd (SHE:002653) announced on Tuesday that it has entered into an exclusive licensing agreement with Nuvectis, a US biotech...
Psilera introduces new synthetic platform to aid neuroplastogen discovery
24 June 2026 - Psilera, a biopharmaceutical company focused on next-generation psychedelics and neuroplastogens, announced on Tuesday a new method for synthesising novel libraries of next-generation n...
EU approves MAVIRET for acute hepatitis C treatment
23 June 2026 - Clinical-stage biotechnology company Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced on Tuesday that its partner AbbVie (NYSE:ABBV) has received European Commission approval for MAVI...